Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Clinical Trial to Determine Recommended Dose and to Assess the Efficacy, Safety and Pharmacokinetic Profile of Oral Paclitaxel(Oraxol®) in Patients With Advanced/Metastatic or Recurrent Gastric Cancer

NCT01491217 is registered in ClinicalTrials.gov with Hanmi Pharmaceutical Company Limited as lead sponsor.

NCT NCT01491217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01491217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Clinical Trial to Determine Recommended Dose and to Assess the Efficacy, Safety and Pharmacokinetic Profile of Oral Paclitaxel(Oraxol®) in Patients With Advanced/Metastatic or Recurrent Gastric Cancer
Lead sponsor
Hanmi Pharmaceutical Company Limited
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2009
Completion date
December 31, 2012
Enrollment
53 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced metastatic gastric cancer, recurrent gastric cancer